Display options
Cite
El-Badry M, Fetih G, Fathy M. Improvement of solubility and dissolution rate of indomethacin by solid dispersions in Gelucire 50/13 and PEG4000. Saudi Pharm J. 2009;17(3):217-25doi: 10.1016/j.jsps.2009.08.006.
El-Badry, M., Fetih, G., & Fathy, M. (2009). Improvement of solubility and dissolution rate of indomethacin by solid dispersions in Gelucire 50/13 and PEG4000. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 17(3), 217-25. https://doi.org/10.1016/j.jsps.2009.08.006
El-Badry, Mahmoud, et al. "Improvement of solubility and dissolution rate of indomethacin by solid dispersions in Gelucire 50/13 and PEG4000." Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society vol. 17,3 (2009): 217-25. doi: https://doi.org/10.1016/j.jsps.2009.08.006
El-Badry M, Fetih G, Fathy M. Improvement of solubility and dissolution rate of indomethacin by solid dispersions in Gelucire 50/13 and PEG4000. Saudi Pharm J. 2009 Jul;17(3):217-25. doi: 10.1016/j.jsps.2009.08.006. Epub 2009 Aug 07. PMID: 23964164; PMCID: PMC3730989.
Copy Download .nbib Format: NLM
Share it on

Saudi Pharm J. 2009 Jul;17(3):217-25. doi: 10.1016/j.jsps.2009.08.006. Epub 2009 Aug 07.

Improvement of solubility and dissolution rate of indomethacin by solid dispersions in Gelucire 50/13 and PEG4000.

Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society

Mahmoud El-Badry, Gihan Fetih, Mohamed Fathy

Affiliations

  1. Department of Pharmaceutics, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia.

PMID: 23964164 PMCID: PMC3730989 DOI: 10.1016/j.jsps.2009.08.006

Abstract

The aim of this study was to prepare and characterize solid dispersions of water insoluble non-steroidal anti-inflammatory drug, indomethacin (IND), with polyethylene glycol 4000 (PEG4000) and Gelucire 50/13 (Gelu.) for enhancing the dissolution rate of the drug. The solid dispersions (SDs) were prepared by hot melting method at 1:1, 1:2 and 1:4 drug to polymer ratios. Scanning electron microscopy (SEM), X-ray powder diffractometry (XRD) and differential scanning calorimetry (DSC) were used to examine the physical state of the drug. Furthermore, the solubility and the dissolution rate of the drug in its different systems were explored. The data from the XRD showed that the drug was still detectable in its solid state in all SDs of IND-Gelu. and disappeared in case of higher ratio of IND-PEG4000. DSC thermograms showed the significant change in melting peak of the IND when prepared as SDs suggesting the change in crystallinity of IND. The highest ratio of the polymer (1:4) enhanced the drug solubility about 4-folds or 3.5-folds in case of SDs of IND-PEG or IND-Gelu., respectively. An increased dissolution rate of IND at pH 1.2 and 7.4 was observed when the drug was dispersed in these carriers in form of physical mixtures (PMs) or SDs. IND released faster from the SDs than from the pure crystalline drug or the PMs. The dissolution rate of IND from its PMs or SDs increased with an increasing amount of polymer.

Keywords: Dissolution rate; Gelucire; Indomethacin; Solid dispersion; Solubility

References

  1. J Pharm Sci. 1971 Sep;60(9):1281-302 - PubMed
  2. Drug Dev Ind Pharm. 2006 Feb;32(2):141-50 - PubMed
  3. Eur J Pharm Biopharm. 2005 Jan;59(1):107-18 - PubMed
  4. Eur J Pharm Biopharm. 2000 Jul;50(1):3-12 - PubMed
  5. J Pharm Sci. 2005 May;94(5):1124-34 - PubMed
  6. J Control Release. 2003 Dec 12;93(3):355-68 - PubMed
  7. Drug Dev Ind Pharm. 2003 Mar;29(3):339-44 - PubMed
  8. Drug Dev Ind Pharm. 2007 Aug;33(8):900-6 - PubMed
  9. Drug Dev Ind Pharm. 2000 Aug;26(8):891-4 - PubMed
  10. J Pharm Pharmacol. 2007 May;59(5):645-53 - PubMed
  11. Int J Pharm. 2002 Mar 20;235(1-2):17-33 - PubMed
  12. Int J Pharm. 2002 Jan 14;231(2):131-44 - PubMed
  13. Eur J Pharm Sci. 2004 Oct;23(2):159-68 - PubMed
  14. Drug Dev Ind Pharm. 2004 Mar;30(3):303-17 - PubMed
  15. Int J Pharm. 1999 Apr 30;181(2):143-51 - PubMed
  16. Eur J Pharm Biopharm. 2007 Nov;67(3):732-42 - PubMed
  17. Pharm Dev Technol. 2007;12(1):43-53 - PubMed
  18. Pharm Dev Technol. 2005;10(4):467-77 - PubMed
  19. Eur J Pharm Biopharm. 2000 Jul;50(1):47-60 - PubMed
  20. Drug Dev Ind Pharm. 1998 Apr;24(4):389-94 - PubMed
  21. Pharm Res. 2007 Mar;24(3):521-9 - PubMed
  22. Eur J Pharm Biopharm. 2005 May;60(1):99-111 - PubMed
  23. Int J Pharm. 2004 Mar 19;272(1-2):1-10 - PubMed
  24. AAPS PharmSciTech. 2006 Feb 10;7(1):E11 - PubMed
  25. Int J Pharm. 2007 Dec 10;345(1-2):95-100 - PubMed
  26. J Pharm Sci. 1997 Jan;86(1):1-12 - PubMed
  27. Eur J Pharm Biopharm. 2007 Jan;65(1):26-38 - PubMed
  28. Pharm Acta Helv. 1978;53(11):327-32 - PubMed
  29. Int J Pharm. 2004 Feb 11;270(1-2):149-66 - PubMed
  30. J Pharm Pharm Sci. 2005 Jan 12;8(1):18-25 - PubMed

Publication Types